Biotoxtech Valuation

Is A086040 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A086040 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A086040's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A086040's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A086040?

Key metric: As A086040 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A086040. This is calculated by dividing A086040's market cap by their current revenue.
What is A086040's PS Ratio?
PS Ratio	1.3x
Sales	₩38.44b
Market Cap	₩50.65b

A086040 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2x
Enterprise Value/EBITDA	-12.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A086040's PS Ratio compare to its peers?

The above table shows the PS ratio for A086040 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.9x
A225220 Genolution	4x	n/a	₩45.4b
A238120 Aligned Genetics	3.1x	n/a	₩46.2b
A245620 Eone Diagnomics Genome Center	0.8x	n/a	₩57.4b
A347740 P&K Skin Research Center	3.8x	n/a	₩61.7b
A086040 Biotoxtech	1.3x	n/a	₩50.6b

Price-To-Sales vs Peers: A086040 is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (2.9x).

Price to Sales Ratio vs Industry

How does A086040's PS Ratio compare vs other companies in the KR Life Sciences Industry?

2 Companies	Price / Sales	Estimated Growth	Market Cap
A245620 Eone Diagnomics Genome Center	0.8x	n/a	US$41.47m
A215380 WOOJUNG BIO	0.6x	n/a	US$20.10m

No more companies available in this PS range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A086040 is good value based on its Price-To-Sales Ratio (1.3x) compared to the KR Life Sciences industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is A086040's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A086040 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A086040's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bioneer

₩529.1b

Operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally.

A064550

₩20,500.00

2.6%

-31.6%

J2KBIO

₩54.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,540.00

3.6%

n/a

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩272,000.00

-3.5%

79.4%